Opus Genetics, Inc. (IRD) Stock: Financials, SEC Filings & Ownership
Opus Genetics, Inc. (IRD) reported trailing twelve-month revenue of $9.9M (down 36.1% year on year) and net income of -$107.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Market cap: $288.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 288.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 15 days
Price
The price chart — with earnings days, unusual moves, 8-Ks and insider trades marked — opens with a free account.
Our verdict
Five questions and why →Our read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysTiming
Today's price conditions
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysAnalyst note
Our written read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysDividends & buybacks
yield — · payout —No dividends or buybacks in the filed statements.
Performance
price return · vs. S&P 500 and the sector| Window | IRD | vs. S&P 500 | vs. sector |
|---|---|---|---|
| 1 month | -28.7% | -27.8% | -34.3% |
| 3 months | +3.6% | +0.8% | -6.1% |
| 6 months | -33.7% | -40.1% | -58.0% |
| Year to date | +63.7% | +52.4% | +48.4% |
| 1 year | +78.0% | +64.1% | +55.1% |
Opus Genetics, Inc. — questions
- What does Opus Genetics, Inc. do?
- Opus Genetics, Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector. Trailing twelve-month revenue: $9.9 million as of 2026-06-30.
- What is Opus Genetics, Inc.'s revenue?
- $9.9M over the twelve months to 2026-06-30, down 36.1% year on year, from its 10-Q and 10-K filings.
- What is Opus Genetics, Inc.'s market cap?
- $288.7M.
- Who owns Opus Genetics, Inc. stock?
- 103 institutions reported Opus Genetics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Nantahala Capital Management (7.4%), Caligan Partners (7.3%), Adage Capital Partners Gp (7.3%).
- When does Opus Genetics, Inc. report earnings?
- Opus Genetics, Inc.'s next earnings report is expected on 2026-11-10.
- What sector is Opus Genetics, Inc. in?
- Opus Genetics, Inc. is in the Healthcare sector, Drug Manufacturers - General industry.
- Who are Opus Genetics, Inc.'s competitors?
- The nearest listed peers by market cap in Drug Manufacturers - General: NovaBridge Biosciences (NBP), GALECTIN THERAPEUTICS INC (GALT), Contineum Therapeutics, Inc. (CTNM), Turn Therapeutics Inc. (TTRX), Benitec Biopharma Inc. (BNTC).
Every figure on this page comes from Opus Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
Source filings: FY2025 10-K · FY2024 10-K · FY2023 10-K · FY2022 10-K · FY2021 10-K · balance sheet 10-Q for 2026-06-30
Peers and related: NovaBridge Biosciences (NBP) · GALECTIN THERAPEUTICS INC (GALT) · Contineum Therapeutics, Inc. (CTNM) · Turn Therapeutics Inc. (TTRX) · Benitec Biopharma Inc. (BNTC) · All Drug Manufacturers - General companies
How these figures are read: methodology · EquiReason.